Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2017

Nov 08, 2017

SELL
$4.7 - $11.7 $470,000 - $1.17 Million
-100,000 Closed
0 $0
Q2 2017

Aug 09, 2017

BUY
N/A
100,000
100,000 $365,000

Others Institutions Holding MRTX

About Mirati Therapeutics, Inc.


  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Hikari Power LTD Portfolio

Follow Hikari Power LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hikari Power LTD, based on Form 13F filings with the SEC.

News

Stay updated on Hikari Power LTD with notifications on news.